Complement dependence of histamine release in chronic urticaria
- PMID: 10400855
- DOI: 10.1016/s0091-6749(99)70129-6
Complement dependence of histamine release in chronic urticaria
Erratum in
- J Allergy Clin Immunol 2000 Feb;105(2 Pt 1):392
Abstract
Background: IgG autoantibodies directed to the alpha-subunit of the IgE receptor have been identified in 30% to 45% of patients with chronic urticaria. However, the exact mechanism by which histamine secretion is initiated is uncertain.
Objective: Histamine release from cutaneous mast cells may occur by cross-linking the IgE receptor or by activation of complement. Our goal is to distinguish these 2 possibilities.
Methods: We incubated human cutaneous mast cells with patient sera, decomplemented sera, or purified patient IgG. The IgG was also added to pooled normal serum or to sera deficient in either C2 or C5, and its ability to activate mast cells was assessed. Mast cells were incubated with human IgE myeloma to saturate alpha-subunits to determine the effect on histamine release.
Results: Patient sera released histamine (18.26% +/- 4.39%), but purified IgG from patients (5.5% +/- 4.3%) did not. Addition of the patient IgG to normal sera rendered the sera positive for histamine-releasing activity (18.4% +/- 4.3%), whereas control IgG or patient IgG added to C2- or C5-deficient sera did not release histamine. Histamine release with decomplemented patient sera was also diminished (8.34% +/- 4.3%). Preincubation of mast cells with a C5-blocking peptide decreased histamine release but was not statistically significant; there was a significant decrease after preincubating mast cells with IgE myeloma.
Conclusion: The degranulation of mast cells by IgG autoantibodies in patients with chronic urticaria requires binding to the IgE receptor and activation of the classical complement cascade. Saturation of the IgE receptor with IgE inhibits such degranulation, presumably by preventing binding of the requisite IgG.
Similar articles
-
A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria.J Allergy Clin Immunol. 2002 Jan;109(1):114-8. doi: 10.1067/mai.2002.120954. J Allergy Clin Immunol. 2002. PMID: 11799375
-
Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria.J Invest Dermatol. 1996 May;106(5):1001-6. doi: 10.1111/1523-1747.ep12338544. J Invest Dermatol. 1996. PMID: 8618029
-
Mechanisms of autoimmune activation of basophils in chronic urticaria.J Allergy Clin Immunol. 2001 Jun;107(6):1056-62. doi: 10.1067/mai.2001.115484. J Allergy Clin Immunol. 2001. PMID: 11398085
-
Pathogenesis of chronic urticaria.Clin Exp Allergy. 2009 Jun;39(6):777-87. doi: 10.1111/j.1365-2222.2009.03256.x. Epub 2009 Apr 22. Clin Exp Allergy. 2009. PMID: 19400905 Review.
-
The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.J Allergy Clin Immunol. 2015 Feb;135(2):337-42. doi: 10.1016/j.jaci.2014.04.036. Epub 2014 Jun 17. J Allergy Clin Immunol. 2015. PMID: 24948369 Review.
Cited by
-
Osteoporosis in Skin Diseases.Int J Mol Sci. 2020 Jul 3;21(13):4749. doi: 10.3390/ijms21134749. Int J Mol Sci. 2020. PMID: 32635380 Free PMC article. Review.
-
Pathophysiology of urticaria.Clin Rev Allergy Immunol. 2006 Feb;30(1):3-11. doi: 10.1385/CRIAI:30:1:003. Clin Rev Allergy Immunol. 2006. PMID: 16461989 Review.
-
Contact urticaria: present scenario.Indian J Dermatol. 2009 Jul;54(3):264-8. doi: 10.4103/0019-5154.55639. Indian J Dermatol. 2009. PMID: 20161861 Free PMC article.
-
Autoimmunity in chronic urticaria and urticarial vasculitis.Curr Allergy Asthma Rep. 2001 Jul;1(4):329-36. doi: 10.1007/s11882-001-0044-0. Curr Allergy Asthma Rep. 2001. PMID: 11892055 Review.
-
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.Int Arch Allergy Immunol. 2020;181(5):321-333. doi: 10.1159/000507218. Epub 2020 Mar 30. Int Arch Allergy Immunol. 2020. PMID: 32224621 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous